文献速递产科母胎医学

不同治疗方式是否影响妊娠期糖尿病女性的动脉僵硬度指标

Does treatment modality affect measures of arterial stiffness in women with gestational diabetes?
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

这项前瞻性纵向队列研究比较了155例低危对照与127例妊娠期糖尿病(GDM)孕妇的动脉僵硬度,GDM按饮食、二甲双胍单药及二甲双胍联合胰岛素分层。结果显示GDM组在孕24+0至35+6周的反射波增强指数显著高于对照,但主动脉脉搏波速度组间无差异;各治疗亚组间无统计学显著差异。

要点

  • GDM孕妇在孕24+0至35+6周的肱动脉及主动脉增强指数显著高于低危对照。
  • 孕36+0周及以后,GDM组与对照组的增强指数无显著差异。
  • 饮食、二甲双胍单药及联合胰岛素三个亚组间的增强指数无统计学显著差异。

核心结论

  • 合并GDM的妊娠无论采用何种治疗方式,其动脉僵硬度均显著高于低危妊娠。
  • 作者认为本研究数据为进一步探究二甲双胍治疗与动脉僵硬度变化及胎盘介导疾病风险的关联提供了基础。

研究设计与样本

  • 前瞻性纵向队列研究,纳入155例低危对照和127例GDM孕妇,GDM中59例饮食干预、47例仅二甲双胍、21例二甲双胍联合胰岛素。
  • 使用Arteriograph®在四个孕周窗口(24+0至27+6周、28+0至31+6周、32+0至35+6周、≥36+0周)测量主动脉脉搏波速度、肱动脉增强指数和主动脉增强指数。
  • 采用线性混合模型分析各动脉僵硬度变量(对数转换),固定效应包括组别、孕周窗口、母亲年龄、种族、产次、体质指数、平均动脉压和心率,个体为随机效应,并用Bonferroni校正P值。

主要发现

  • 研究组与孕周的两阶交互项对肱动脉增强指数和主动脉增强指数显著(P<0.001),但无证据表明平均主动脉脉搏波速度在各研究组间不同(P=0.729)。
  • 对照组在W1至W3的肱动脉增强指数和主动脉增强指数显著低于合并GDM组,但在W4不显著。
  • 对数转换后肱动脉增强指数的平均差异在W1为-0.37(95%CI -0.52至-0.22)、W2为-0.23(95%CI -0.35至-0.12)、W3为-0.29(95%CI -0.40至-0.18)。
  • 对数转换后主动脉增强指数的平均差异在W1为-0.49(95%CI -0.69至-0.30)、W2为-0.32(95%CI -0.47至-0.18)、W3为-0.38(95%CI -0.52至-0.24)。
  • 对照组在W1至W3的肱动脉增强指数和主动脉增强指数也显著低于各GDM治疗亚组(饮食、仅二甲双胍、二甲双胍联合胰岛素);各治疗组间平均差异在任何孕周窗口均无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether arterial stiffness (AS) differs between healthy women and women with gestational diabetes mellitus (GDM) managed by different treatment modalities. METHODS: This was a prospective longitudinal cohort study comparing AS in pregnancies complicated by GDM and low-risk controls. AS was assessed by recording aortic pulse-wave velocity (AoPWV), brachial augmentation index (BrAIx) and aortic augmentation index (AoAIx) using the Arteriograph® at four gestational-age windows: 24 + 0 to 27 + 6 weeks (W1); 28 + 0 to 31 + 6 weeks (W2); 32 + 0 to 35 + 6 weeks (W3) and ≥ 36 + 0 weeks (W4). Women with GDM were considered both as a single group and as subgroups stratified by treatment modality. Data were analyzed using a linear mixed model on each AS variable (log-transformed) with group, gestational-age window, maternal age, ethnicity, parity, body mass index, mean arterial pressure and heart rate as fixed effects and individual as a random effect. We compared the group means including relevant contrasts and adjusted the P-values using Bonferroni correction. RESULTS: The study population comprised 155 low-risk controls and 127 women with GDM, of whom 59 were treated with dietary intervention, 47 were treated with metformin only and 21 were treated with metformin + insulin. The two-way interaction term of study group and gestational age was significant for BrAIx and AoAIx (P < 0.001), but there was no evidence that mean AoPWV was different between the study groups (P = 0.729). Women in the control group demonstrated significantly lower BrAIx and AoAIx compared with the combined GDM group at W1-W3, but not at W4. The mean difference in log-transformed BrAIx was -0.37 (95% CI, -0.52 to -0.22), -0.23 (95% CI, -0.35 to -0.12) and -0.29 (95% CI, -0.40 to -0.18) at W1, W2 and W3, respectively. The mean difference in log-transformed AoAIx was -0.49 (95% CI, -0.69 to -0.30), -0.32 (95% CI, -0.47 to -0.18) and -0.38 (95% CI -0.52 to -0.24) at W1, W2 and W3, respectively. Similarly, women in the control group also demonstrated significantly lower BrAIx and AoAIx compared with each of the GDM treatment subgroups (diet, metformin only and metformin + insulin) at W1-W3. The increase in mean BrAIx and AoAIx seen between W2 and W3 in women with GDM treated with dietary management was attenuated in the metformin-only and metformin + insulin groups. However, the mean differences in BrAIx and AoAIx between these treatment groups were not statistically significant at any gestational-age window. CONCLUSIONS: Pregnancies complicated by GDM demonstrate significantly higher AS compared with low-risk pregnancies regardless of treatment modality. Our data provide the basis for further investigation into the association of metformin therapy with changes in AS and risk of placenta-mediated diseases. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Anness AR, Nath M, Osman MW, et al. Does treatment modality affect measures of arterial stiffness in women with gestational diabetes? Ultrasound Obstet Gynecol. 2023. PMID: 37099764. doi:10.1002/uog.26234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。